𝔖 Bobbio Scriptorium
✦   LIBER   ✦

P377 Safety profile and discontinuation rate of infliximab and adalimumab in patients with Crohn's disease and ulcerative colitis: experience from a tertiary care hospital in Qatar over a 7 year period

✍ Scribed by Sharma, M.; Al Kaabi, S.; Al Dweik, N.; John, A.; Wani, H.; Al Ejji, K.; Al Mohanadi, M.; Derbala, M.; Yacoub, R.; Pasic, F.; Butt, T.; ElBedawi, M.; Singh, R.


Book ID
123555262
Publisher
Oxford University Press
Year
2013
Tongue
English
Weight
52 KB
Volume
7
Category
Article
ISSN
1873-9946

No coin nor oath required. For personal study only.